New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 7, 2012
07:36 EDTCYTKCytokinetics presents analyses from Tirasemtiv clinical trials in ALS patients
Cytokinetics announced a platform presentation of pharmacokinetic data and pharmacokinetic/pharmacodynamic analyses from three previously-reported clinical trials of tirasemtiv in patients with amyotrophic lateral sclerosis, or ALS, at the 23rd International Symposium on ALS and Motor Neurone Diseases, or ALS/MND, in Chicago, IL. Tirasemtiv selectively activates the fast skeletal muscle troponin complex by increasing its sensitivity to calcium, which increases skeletal muscle force in response to neuronal input. In preclinical studies, this mechanism has been shown to delay the onset and reduce the degree of muscle fatigue. Tirasemtiv is currently being evaluated in BENEFIT-ALS, an international, double-blind, randomized, placebo- controlled, Phase IIb clinical trial designed to evaluate the safety, tolerability and potential efficacy of this novel drug candidate in patients with ALS.
News For CYTK From The Last 14 Days
Check below for free stories on CYTK the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 15, 2014
07:21 EDTCYTKHeart Failure Society of America to hold annual meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use